The therapeutic effects of vitamin D3 and its analogues in psoriasis

Bibliography

• MORIMOTO S, YOSHIKAWA K: A patient with psoriasis cured by 1-alpha-hydroxyvitamin D3. Med. J. Osaka Univ. (1985) 35:51–54.
   PubMedGoogle Scholar
• •The first demonstration of vitamin D's efficacy in psoriasis
   Google Scholar
• MORIMOTO S, YOSHIKAWA K, KOZUKA T et al.: An open study of vitamin D3 treatment in psoriasis vulgaris. Br. I Dermatol. (1986) 115:421–429.
   PubMed Web of Science ®Google Scholar
• SMITH EL, PINCUS SH, DONOVAN L, HOLICK MF: A novel approach for the evaluation and treatment of psoria-sis. Oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy for psoriasis. JAAD (1988) 19:516–528.
   Google Scholar
• BOISSEAU-GARSAUD AM, LEGRAIN V, HEHUNSTRE JP, MALEVILLE J, TAIEB A: Traitement du psoriasis par le calcitriol per os. Etude de cinq observations et revue de la littérature. Ann. Dermatol. Venereol. (1993) 120:669–674.
   PubMed Web of Science ®Google Scholar
• KATO T, ROKUGO M, TERUI T et al.: Successful treat-ment of psoriasis with topical application of the active vitamin D3 analogue, 1,24-dihydroxycholecalciferol. Br. J. Dermatol. (1986) 115:431–433.
   PubMed Web of Science ®Google Scholar
• KRAGBALLE K, BECK H I, SOGAARD H: Improvement of psoriasis by a topical vitamin D3 analogue (MC903) in a double-blind study. Br. J. Dermatol. (1988) 119:223–230.
   PubMed Web of Science ®Google Scholar
• BERNED F, MAGNALDO T, DARMON M: Delayed onset of epidermal differentiation in psoriasis. J. Invest. Derma-tol. (1992) 98:902–910.
   PubMed Web of Science ®Google Scholar
• MILS V, BASSET-SEGUIN N, MOLES JP et al.: Comparative analysis of normal and psoriatic skin both in vivo and in vitro. Differentiation (1994) 58:77–86.
   PubMed Web of Science ®Google Scholar
• SCHLAAK JF, BUSLAU M, JOCHUM W et al.: T-cells in-volved in psoriasis vulgaris belong to the Thl subset. J. Invest. Dermatol. (1994) 102:145–149.
   PubMed Web of Science ®Google Scholar
• NICKOLOFF J: The cytokine network in psoriasis. Arch. Dermatol. (1991) 27:871–885.
   Google Scholar
• •A review of skin immune phenomena.
   Google Scholar
• GRIFFITHS CEM: Cutaneous leukocyte trafficking and psoriasis. Arch. Dermatol. (1994) 130:494–499.
   PubMed Web of Science ®Google Scholar
• •A review of skin immune phenomena.
   Google Scholar
• VOORHEES JJ, DUELL EA, BASS LJ, POWEL JA, HARRELL ER: Decreased cyclic AMP in the epidermis of lesions of psoriasis. Arch. Dermatol. (1972) 105:695.
   PubMed Web of Science ®Google Scholar
• HORN F, MARKS F, FISHER GJ, MARCELO CL, VOORHEES JJ. Decreased protein kinase C activity in psoriatic ver-sus normal epidermis. J. Invest. Dermatol. (1987) 88:220–222.
   Google Scholar
• ELDER JT, FISHER GJ, LINDQUIST PB et al.: Overexpres-sion of transforming growth factor in psoriatic epider-mis. Science (1989) 243:811–814.
   PubMed Web of Science ®Google Scholar
• BASSET-SEGUIN N, ESCOT C, MOLES JP et al.: C-fos and Crjun proto-oncogene expression is decreased in pso-riasis: a in situ quantitative analysis. J. Invest. Dermatol. (1991) 97:672–678.
   PubMed Web of Science ®Google Scholar
• CARROLL JM, ROMERO MR, WATT FM: Suprabasal in-tegrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype re-sembling psoriasis. Cell (1995) 83:957–968.
   PubMed Web of Science ®Google Scholar
• GUILHOU JJ, MEYNADIER J, CLOT J: New concepts in the pathogenesis of psoriasis. Br. J. Dermatol. (1978) 98:585–592.
   PubMed Web of Science ®Google Scholar
• •The relationship between immunogical disturbances and keratinocyte proliferation.
   Google Scholar
• BATA-CSORGO Z, HAMMERBERG C, VOORHEES JJ, COO-PER KD: Intralesional lymphocyte activation as a me-diator of psoriatic epidermal hyperplasia. J. Invest. Dermatol. (1995) 105:895–945.
   Google Scholar
• WRONE-SMITH T, NICKOLOFF BJ: Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. (1996) 98:1878–1887.
   PubMed Web of Science ®Google Scholar
• GOTTIEB SL, GILLEAUDEAU P, JOHNSON R et al.: Re-sponse of psoriasis to a lymphocyte selective toxin (DAB38911-2) suggests a primary immune, but not keratinocyte pathogenic basis. Nature Medicine (1995) 1:442–447.
   PubMed Web of Science ®Google Scholar
• GROSSMAN RM, CHEVRET S, ABI-RACHED J, BLANCHETF, DUBERTRET L: Long-term safety of cyclosporine in the treatment of psoriasis. Arch. Dermatol. (1996) 132:623–629.
   PubMedGoogle Scholar
• THE EUROPEAN FK 506 MULTICENTRE PSORIASIS STUDY GROUP: Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch. Dermatol. (1996) 132:419–423.
   PubMed Web of Science ®Google Scholar
• ROBINET E, STAMM C, MOREL P et al.: Clinical improve-ment of a patient with severe psoriasis following CD4 antibody administration despite a blocking antibody-host response. Eur. J. Dermatol. (1996) 6:141–146.
   Web of Science ®Google Scholar
• LEUNG DYM, WALSH P, GIORNO R, NORRIS DA: A poten-tial role for superantigens in the pathogenesis of pso-riasis. J. Invest. Dermatol. (1993) 100:225–228.
   PubMed Web of Science ®Google Scholar
• HENSELER T: The genetics of psoriasis. JAAD (1997) 37:S1–S11.
   Google Scholar
• •An exhaustive up-to-date review.
   Google Scholar
• PILLAI S, BIKLE DD, ELIAS PM: Vitamin D and epidermal differentiation: evidence for a role of endogenously produced vitamin D metabolites in keratinocyte differ-entiation. Skin Pharmacol. (1988) 1:149–160.
   PubMedGoogle Scholar
• CARLBERG C: Mechanisms of nuclear signalling by vita-min D: interplay with retinoid and thyroid hormone signalling. Eur. J. Biochem. (1995) 231:517–527.
   PubMedGoogle Scholar
• CARLBERG C: The concept of multiple vitamin D signal-ing pathways. Invest. Dermatol. Symp. Proc. (1996) 1:10–14.
   Google Scholar
• BIKLE DD: 1,25 (OH)2D3-modulated calcium induced keratinocyte differentiation. J. Invest. Dermatol. Symp. Proc. (1996) 1:22–27.
   PubMedGoogle Scholar
• GNIADECKI R: Vitamin D - a modulator of cell prolifera-tion. Retinoids (1997)13:55–59.
   Google Scholar
• •A review of antineoplastic properties.
   Google Scholar
• GNIADECKI R: Activation of raf-mitogen-activated pro-tein kinase signalling pathway by 1,25-dihydroxyvitamin D3 in normal human keratinocytes. J. Invest. Dermatol. (1996) 106:1212–1217.
   PubMed Web of Science ®Google Scholar
• BIKLE DD, GEE E, PILLAI S: Regulation of keratinocyte growth differentiation and vitamin D metabolism by analogs of 1,25-dihydroxyvitamin D. J. Invest. Dermatol. (1993) 101:713–718.
   PubMed Web of Science ®Google Scholar
• BLUMENBERG M, CONNOLLY DM, FREEDBERG I: Regula- tion of keratin gene expression: the role of the nuclear receptors for retinoic acid, thyroid hormone, and vita-min D3. J. Invest. Dermatol. (1992) 98:42S–49S.
   Google Scholar
• BENASSI L, OTTANI D, FANTINI F et al.: 1, 25 - dihydroxyvitamin D3 transforming growth factor be-tal, calcium, and ultraviolet B radiation induce apop-tosis in cultured human keratinocytes. J. Invest Dermatol. (1997) 109:276–282.
   PubMed Web of Science ®Google Scholar
• TEXEREAU M, VIAC J: Vitamin D, immune system and skin. Eur. J. Dermatol. (1992) 2:258–264.
   Google Scholar
• •A review.
   Google Scholar
• BARNA M, BOS JD, KAPSENBERG ML, SNIJDEWINT FGM: Effect of calcitriol on the production of T-cell-derived cytokines in psoriasis. Br. J. Dermatol. (1997) 136:536–541.
   PubMed Web of Science ®Google Scholar
• STABERG B, OXHOLM A, KLEMP P, CHRISTIANSEN C: Ab-normal vitamin D metabolism in patients with psoria-sis. Acta Dermatol. Venereol. (1987) 67:65–68.
   PubMed Web of Science ®Google Scholar
• GUILHOU JJ, COLETTE C, MONPOINT S, LANCRENON E,GUILLOT B: Vitamin D metabolism in psoriasis before and after phototherapy. Acta Dermatol. Venereol. (1990) 70:351–354.
   PubMed Web of Science ®Google Scholar
• STABERG B, OXHOLM A, KLEMP P, HARTWELL D: Is theeffect of phototherapy in psoriasis partly due to an im-pact on vitamin D metabolism? Acta Dermatol. Venereol. (1988) 68:436–439.
   Google Scholar
• PEREZ A, RAAB R, CHEN TC, TURNER A, HOLICK MF:Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br. J. Dermatol. (1996) 134:1070–1078.
   PubMed Web of Science ®Google Scholar
• •An open trial in 85 patients.
   Google Scholar
• VAN DE KERKHOF PCM, VAN BOKHOVEN M, ZULTAK M,CZARNETZKI BM: A double-blind study of topical 1,25-dihydroxyvitamin D3 in psoriasis. Br. J. Dermatol. (1989) 120:661–664.
   PubMed Web of Science ®Google Scholar
• LANGNER A, ASHTON P, VAN DE KERKHOF PCM, VER-JANS H: A long-term multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis. Br. J. Dermatol. (1996) 135:385–389.
   PubMed Web of Science ®Google Scholar
• WISHART JM: Calcitriol (1,25-dihydroxyvitamin D3) ointment in psoriasis, a safety tolerance and efficacy multicentre study. Dermatology (1994) 188:135–139.
   PubMed Web of Science ®Google Scholar
• PEREZ A, CHEN TC, TURNER A et al.: Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br. J. Dermatol. (1996) 134:238–246.
   PubMed Web of Science ®Google Scholar
• NISHIMURA M, HORI Y, NISHIYAMA S, NAKAMIZO Y: Topical 1,24 (R)-dihydroxyvitamin D3 for the treat-ment of psoriasis. Review of the literature. Eur. J. Der-matol. (1993) 3:255–261.
   Google Scholar
• VAN DE KERKHOF PCM, WERFEL T, HAUSTEIN UF et al.:Tacalcitol ointment in the treatment of psoriasis vul-garis; a multicentre, placebo-controlled, double-blind study on efficacy and safety. Br. J. Dermatol. (1996) 135:758–765.
   Google Scholar
• VEIEN NK, BJERKE JR, ROSSMANN-RINGDAHL I, JAKOB-SEN HB: Once daily treatement of psoriasis with tacal-citol compared with twice daily treatment with calcipotriol. Br. J. Dermatol. (1997) 137:581–586.
   PubMed Web of Science ®Google Scholar
• KRAGBALLE K, WILDFANG IL: Calcipotriol (MC 903) a novel vitamin D3 analogue stimulates terminal differ-entiation and inhibits proliferation of cultured human keratinocytes. Arch. Dermatol. Res. (1990) 282:164–167.
   PubMed Web of Science ®Google Scholar
• KRAGBALLE K: Treatment of psoriasis with calcipotriol and other vitamin D analogues. JAAD (1992) 27:1001–1008.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review up to 1992.
   Google Scholar
• CUNLIFFE WJ, BERTH-JONES J, CLAUDY A et al.: Com-parative study of calcipotriol (MC903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. JAAD (1992) 26:736–743.
   PubMed Web of Science ®Google Scholar
• THAM SN, CHEONG WK: A comparative study of calci-potriol ointment and tar in chronic plaque psoriasis. Br. J. Dermatol. (1994) 131:673–677.
   PubMed Web of Science ®Google Scholar
• BERTH-JONES J, CHU AC, DODD WAH et al.: A multicen-tre, parallel-group comparison of calcipotriol oint-ment and short-contact dithranol therapy in chronic plaque psoriasis. Br. J. Dermatol. (1992) 127:266–271.
   PubMed Web of Science ®Google Scholar
• GROSSMAN RM, THIVOLET J, CLAUDY A et al.: A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose vulgaris. JAAD (1994) 31:68–74.
   PubMed Web of Science ®Google Scholar
• SPEIGHT EL, FARR PM: Calcipotriol improves the re-sponse of psoriasis to PUVA. Br. J. Dermatol. (1994) 30:79–82.
   Google Scholar
• KRAGBALLE K: Combination of topical calcipotriol (MC903) and UVB radiation for psoriasis cyclospor-ine: results of a multicenter placebo-controlled study. Dermatologica (1990) 181:211–214.
   PubMedGoogle Scholar
• LEBWOHL M, HECKER D, MARTINEZ J, SAPADIN A, PATEL B: Interactions between calcipotriene and ultraviolet light. JAAD (1997) 37:93–95.
   PubMed Web of Science ®Google Scholar
• MCKENNA KA, STERNE RS: Photosensitivity associated with combined UV-B and calcipotriene therapy. Arch. Dermatol. (1995) 131:1305–1307.
   PubMed Web of Science ®Google Scholar
• ORTONNE JP: Psoriasis: nouvelle modalité therapeu-tique par le calcipotriol plus le dipropionate de bétaméthasone. Nouv. Dermatol. (1994) 13:746–751.
   Google Scholar
• KIENBAUM S, LEHMANN P, RUZICKA T: Topical calcipo-triol in the treatment of intertriginous psoriasis. Br. J. Dermatol. (1996) 135:647–650.
   PubMed Web of Science ®Google Scholar
• DARLEY CR, CUNLIFFE WJ, HUTCHINSON PE, KLABER MR, DOWNES N: Safety and efficacy of calcipotriol oint-ment (Dovonex R) in treating children with psoriasis vulgaris. Br. J. Dermatol. (1996) 135:390–393.
   PubMed Web of Science ®Google Scholar
• FULLERTON A, AVNSTORP C, AGNER T et al.: Patch test study with calcipotriol ointment in different patient groups, including psoriatic patients with and without adverse dermatitis. Acta Dermatol. Venereol. (1996) 76:194–202.
   PubMed Web of Science ®Google Scholar
• GIORDANO-LABADIE F, LAPLANCHE G, BAZEX J: Eczema de contact au calcipotriol. Ann. Dermatol. Venereol. (1996) 123:196–197.
   PubMed Web of Science ®Google Scholar
• GUZZO C, LAZARUS G, GOFFE BS et al.: Topical calcipo-triene has no short-term effect on calcium and bone metabolism of patients with psoriasis. JAAD (1996) 34:429–433.
   PubMed Web of Science ®Google Scholar
• BINDERUP L, LATINI S, BINDERUP E et al.: 20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem. Pharmacol. (1991) 42:1569–1575.
   PubMed Web of Science ®Google Scholar
• GNIADECKI R: Effects of 1,25-dihydroxyvitamin D3 and its 20-epi analogues (MC 1288, MC 1301, KH 1060), on clonal keratinocyte growth: evidence for differentia-tion of keratinocyte stem cells and analysis of the modulatory effects of cytokines. Br. I PharmacoL (1997) 120:1119–1127.
   PubMed Web of Science ®Google Scholar
• KRAGBALLE K, DAM TN, HANSEN ER et al • Efficacy andsafety of the 20-epi-vitamin D3 analoge KH 1060 in the topical therapy of psoriasis: results of a dose-ranging study. Acta Dermatol. Venereol. (1994) 74:398–402.
   PubMed Web of Science ®Google Scholar
• VAN DE KERKHOF PCM. Biological activity of vitamin Danalogues in the skin with special reference to antip-soriatic mechanisms. Br.]. Dermatol. (1995) 132:675–682.
   PubMed Web of Science ®Google Scholar
• •An excellent review of in vitro and in vivo effects.
   Google Scholar
• ANZANO MA, SMITH JM, USKOKOVIC MR et al.: 1,25-dihydroxyl6ene23yn26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res. (1994) 54:1653–1656.
   PubMed Web of Science ®Google Scholar
• COLSTON KW, MACKAY AG, JAMES SY et al.: EB 1089 a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Phar-macol. (1992) 44:2273–2280.
   PubMed Web of Science ®Google Scholar
• KRAGBALLE K, STEIJLEN PM, IBSEN HH et al.: Efficacy tol-erability and safety of calcipotriol ointment in disor-ders of keratinization. Arch. Dermatol. (1995) 131:556–560.
   PubMed Web of Science ®Google Scholar
• HUMBERT P, DUPOND JL, AGACHE P et al.: Treatment of scleroderma with oral 1,25-dihydroxyvitamin D3: evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial. Acta Dermatol. Venereol. (1993) 73:449–451.
   PubMed Web of Science ®Google Scholar
• MILS V, BASSET-SEGUIN N, MOLES JP, GUILHOU JJ: 1,25-dihydroxivitamin D3 and its synthetic derivatives MC903 and EB 1089 induce a partial tumoral pheno-type reversal in a skin-equivalent system. J. Invest. Der-matol. Symp. Proc. (1996) 1:87–93.
   PubMedGoogle Scholar